{
    "clinical_study": {
        "@rank": "153184", 
        "arm_group": [
            {
                "arm_group_label": "Hydroquinone", 
                "arm_group_type": "Experimental", 
                "description": "Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.\nHalf of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.\nIt will be applied daily, at night, during 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.\nHalf of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.\nIt will be applied daily, at night, during 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce\n      melasma on the face, using a split-face randomization design, evaluating the MASI Score from\n      baseline to week 4 and week 8, in both half-faces receiving active treatment vs. placebo.\n\n      To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the\n      face.\n\n      To assess patients' satisfaction regarding Melanoderm 4% Crema after 8 weeks."
        }, 
        "brief_title": "Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Facial Melasma", 
        "condition_browse": {
            "mesh_term": "Melanosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult women aged between 18-65 years old.\n\n          -  Fitzpatrick phototypes I to IV.\n\n          -  Presenting moderate to severe facial melasma facial, with a basal Melasma Area and\n             Severity Index (MASI Index) between 10 and 20.\n\n          -  Women of childbearing potential must use an adequate contraceptive method to avoid\n             pregnancy and must have a negative pregnancy test in a maximum of 72 hours before\n             receiving the trial treatment.\n\n          -  Breastfeeding women will not be included in the study.\n\n          -  Having given freely and expressly her informed consent.\n\n        Exclusion Criteria:\n\n          -  Those with any history of allergy or hypersensitivity to a cosmetic product,\n             hydroquinone, or one of the ingredients of the investigational products.\n\n          -  Fitzpatrick phototype V.\n\n          -  Skin pigmentation diseases different to melasma.\n\n          -  Evidence of active cancer disease or diagnosis of cancer in the last year.\n\n          -  Those receiving any topical or oral treatment that could interfere with melasma.\n\n          -  Pregnant or breastfeeding women, or those expecting to get pregnant during the study.\n\n          -  Evidence or suspicion of low compliance with the study visits and procedures.\n\n          -  Participation in other clinical trial simultaneously or in the previous 3 months."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095990", 
            "org_study_id": "ECM2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hydroquinone", 
                "intervention_name": "Hydroquinone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hydroquinone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Facial Melasma", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "email": "susipuig@gmail.com", 
                "last_name": "Susana Puig, MD", 
                "phone": "93 227 98 64"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Clinic de Barcelona"
            }, 
            "investigator": {
                "last_name": "Susana Puig, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study", 
        "other_outcome": {
            "description": "Patients' satisfaction in terms of efficacy and safety will be evaluated by a Visual Analogic Scale at week 8, which will be completed for each side of the face independently.", 
            "measure": "To assess patients' satisfaction regarding Melanoderm 4% Crema.", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "overall_contact": {
            "email": "fgarranz@mesoestetic.com", 
            "last_name": "Francisco Garc\u00eda", 
            "phone": "+34 902 26 20 31"
        }, 
        "overall_contact_backup": {
            "email": "l.plasencia@dynasolutions.com", 
            "last_name": "Liana de Plasencia", 
            "phone": "+34 91 456 1105"
        }, 
        "overall_official": {
            "affiliation": "Hospital Clinic de Barcelona", 
            "last_name": "Susana Puig, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy assessments will be measured by the Melasma Area and Severity Index (MASI Index) at baseline, week 4 and week 8 (end of treatment).", 
            "measure": "To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face.", 
            "safety_issue": "No", 
            "time_frame": "Baseline, week 4, week 8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095990"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be recorded throughout the study and 30 days after the end of treatment.", 
            "measure": "To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the face.", 
            "safety_issue": "Yes", 
            "time_frame": "Week 4, Week 8, Follow-up period (Week 12)"
        }, 
        "source": "Mesoestetic Pharma Group S.L.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mesoestetic Pharma Group S.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}